Minggu, 12 Desember 2021

AIMEDIS

AIMEDIS 

Potential purchasers of Aimedis digital assets (as referred to in this whitepaper) must carefully consider and evaluate all risks and uncertainties associated with Aimedis, its assets, its subsidiary business, the companies’ operations, the asset offering, the AIMX tokens and all information presented in this whitepaper and the Aimedis business plan, the technical documents and all information provided on all Aimedis associated websites and social media presences.

In case any of these uncertainties, risks or problems develop into actual events, the companies, the business operations, the financial state of the companies, effect and results of Aimedis operations and material provided with Aimedis could be materially and adversely affected. In case of one of these events you might lose part or all of the value of the acquired assets.

This business plan and its contained information shall not be considered legal, financial, business, tax or investment advice concerning Aimedis and its assets and its associates’ businesses and operations. Please always advise your own tax advisor, your legal or any other professional advisor or your local authorities when you plan to participate in Aimedis. Please always be aware that you might bear the financial risks of any participation in Aimedis for an indefinite period.

The business plan you are reading does not represent an offer document of any kind or prospectus and is not intended to illustrate a solicitation for investment in securities or offer of securities in any jurisdiction.

 

OVERVIEW OF AIMEDIS ECOSYSTEM

Ideally situated in the Netherlands, Dubai and the Philippines, Aimedis has a vast network of doctors and supporters who are actually establishing Aimedis as a key player in the healthcare environment, delivering services to a growing community of empowered patients.

Aimedis is offering international coding of diagnoses and medication correspondent to WHOstandards. Our unique solution includes seamless integration into the existing health IT environment and support for all major medical standards like HIPAA compliance, IHE compatibility, ISO certification, HL7/FHIR, SNOMED, LOINC, ICD-10, ATC and more. Besides Aimedis already is a registered medical product in the European Union. The Aimedis platform offers a complete e-health ecosystem consisting of several and expandable modules.

The entire platform is supported by our AIMChain 2.0 blockchain secured data structure which secures all parts and information that is shared and accessed in Aimedis. The ecosystem will use artificial intelligence in several ways (see Artificial Intelligence Supported Therapy, Diagnosis and Research).

The Aimedis ecosystem consists of the Aimedis patient centered platform, the professional platform, AIMSocial + user content (video and more), Aimedis Labs & Pharmacy, Medical Tourism applications, Aimedis records, video chat, prescriptions, second opinions, appointments and Aimedis Virtual Hospital, all available on web and mobile, multilingual and web responsive. This means Aimedis is not only a fully functional combination of a personal health record and an electronic medical record but it combines the HIPAA/IHE compliant EMR/PHR with a fully HIPAA compliant video bridge between doctors and patients, an electronic prescription module, an electronic appointment system, an electronic learning & teaching section, a medical video library, an AI backed big data evaluation, AI supported pharmaceutical treatments, a medical tourism platform and a social platform secured by our proprietary AIMChain blockchain to give patients security, 100% transparency and trust by securing each and every single transaction. This finally gives patients not a dead data silo but a fully trustworthy solution to bring their healthcare to a new level and make them the owner and director of their private medical data.

 

AIMSOCIAL – DECENTRALIZED & INCENTIVIZED MEDICAL SOCIAL NETWORKING

AIMSocial is our medical social media platform. It creates a space where patients support each other to live a happier and healthier life. Within this robust community, patients can share their experiences with diseases, effects of treatments and all kinds of information about health issues, wellness and nutrition. That’s where Aimedis finally combines empiric medical data with perceived data by the community bringing healthcare professionals together with the swarm intelligence of patient groups to reach new levels of medical support and quality.

We know of a variety of chronic diseases where in a lot of health cases people benefit more from talking with and learning from other similarly affected people than they do from talking to doctors and nurses. They can share subjective experiences with therapies, drugs and symptoms, as well as situations of everyday life with partners, family and environment. Learning to cope with a family member with dementia is a common challenge. After a diagnosis, caregivers begin looking for information and for others who have already dealt with the same experience for advice andknowledge. For those facing a harsh diagnosis or unexpected trauma and recovery, a community of peers becomes a lifeline to help to deal with the condition and navigate through new treatments and protocols.

The impact of health information delivered via mobile applications is vital, especially in regions with poor infrastructure. Many studies report significant drops in HIV-infections after people are informed about risks and prevention. Education and awareness can be enhanced by health professionals using the social media platform to reach out to people both near and far. Individuals that contribute useful information to others and create a community of followers will be incentivized. Building a community of responsible, supportive and caring people will be one of our major efforts. The Aimedis Social Medical Network also consists of medical influencers, that are doctors, nurses or healthcare specialists from other fields of healthcare to support patients via videos, streams, content and more. The Aimedis blockchain plays a major role when it comes to securing and incentivizing people for their efforts.

 

MEDICAL TOURISM & THE BLOCKCHAIN

Medical tourism is emerging all around the globe, with countries like Turkey, India, Thailand and even European nations competing to offer a wide range of specialized medical treatments. These offerings are ideal for patients who want quality and cost-effective medical care. This trend towards medical tourism is driven by an increasing access to high-quality care and services in low-cost countries or lack of availability and affordability of treatments in a patient‘s homeland. How is Aimedis strategically positioned to take advantage of this unique situation?

We not only establish the connection between patient and care provider, but we also compare prices and get the best deal for the patient, making it easier than ever to find the care needed. We also store and keep all the related information inside the patients’ records and connect the patients’ treating doctors before, during and after the intended procedures. This practice ensures transparency for the patient inside the AIMChain 2.0 by making the patients’ data incorruptible and 100% genuine. It also guarantees the integrity and security of the transaction and the procedure for the patient, enhancing both safety and results.

 

THE FIRST MEDICAL & SCIENTIFIC NFT MARKETPLACE

  • Asset type: Aimedis ERC-721 based NFTs

  • Mechanism of deployment: generated inside the Aimedis DataXChange platform

  • Price per NFT: medical and research data at market prices (up to several thousand USD / NFT)

  • Aimedis NFTs contain medical / Pharmaceutical / Research / socio-economic data

  • Patients / Researchers / Pharma / CRO / universities & governments can buy & sell data directly via the platform

  • Multi ownership of NFTs - Pharma companies, research companies and universities can share the funding and acquire medical data together

  • Data providers earn a fix percentage of the data sold each time the NFT is used and / or sold

  • Each NFT is flawlessly traceable while always keeping the data provider's anonymity if selected (research institutes / CRO / pharma etc. can sell data while providing their ID)

  • Each NFT is encrypted so that only the data buyer can access it while a new private key is generated each time the data is sold and passed on

Option to move NFTs inside Aimedis' scientifical parachain (encrypted, not public)

After establishing fix values for data NFTs will get color codes to fix a value (e.g. 4.000 USD for a red NFT) to give researchers / patients / universities the option to trade & lend projects or cash against medical data making using the AIMX token, upgrading the AIMX token to a De-Fi token (2023)

Aimedis NFTs can be defined as SINGLE USE NFTs or MULTI USE NFTs. While SINGLE USE NFTs are being burned after the first access, MULTI USE NFTs can be used multiple times AIMX token holders get discounts on publishing AND buying NFTs

  • NFT usage in the AIMx ecosystem -> stake AIMx and get

  • NFT prizes like tickets for healthcare programs

  • The Aimedis NFT marketplace is called Aimedis DataXChange and works as the world's first medical & scientific NFT platform - 21st century data integrity & monetization system.

image.png

The Aimedis AIMX token

  • Asset type: BEP-20 on Binance Smart Chain

  • Maximal supply: 600,000,000 AIMx

  • AIMx Sale: 60,000,000 AIMx

  • 1 AIMx = 0,05 EUR/USD

  • Staking: 1 Stake = 200,000 AIMx. A min. of 200k AIMx is required to participate in staking program. Stake for 12 months, receive 12.5% interest in AIMx. E.g.: User A stakes 200.000 AIMx for 12months => 12,5% interest (25.000 AIMx Tokens). Lockup time for staking is at least 6 months.

  • Burning: 2% of existing AIMx tokens are burned per year for 5 years. Afterwards decentralized governance will decide about the continuation of the burning program.

  • Spending: AIMx gives patients/users 10% discount on services when used in payments. Healthcare providers & companies receive up to 50% discount on advertising costs on the platform, if they hold a min. of 1 stake (200k AIMx). Pharmacies can access business deals within the Aimedis ecosystem if they hold a min. of 1 stake (200k AIMx). Users can use AIMx to get enable social medical functions.

  • Earning: AIMx rewards for social medical activities (users, creators, vloggers, influencers, moderators, surveys, focus groups); AIMx donations for Nonprofits or goodwill initiatives (Africa, Philippines, Malaysia); AIMx funding for creatives projects to spread awareness (HIV/AIDS, rare diseases, etc); Advocacy programs for workplaces (hospitals, clinics, pharmacies) where participants can raise their Aimedis score and AIMx to unlock premium features (e.g. staffing premium services); earn AIMx, perks, and premium access by building local communities as an Aimedis ambassador.

TOTAL AMOUNT OF AIMX TOKENS

  • 600,000,000 AIMX

PRIVATE & PUBLIC SALE

  • 60,000,000 AIMX
  • Seed: 24M AIMX
  • Private Sale: 32M AIMX
  • IDO: 4M AIMX

PRICE PER AIMX TOKEN

  • 0,05 USD IDO & Pancakeswap@launch
  • RELATION AIMEDIS NTFs
  • Get a Discount on buying and selling NFTs via the platform
  • Trading NFTs for loan / research funds project funds
  • Ecosystem incentives: 30%
  • Treasury: 20%
  • Staking rewards: 20%
  • Private & public sale: 10%
  • Aimedis foundation: 10%
  • Team & advisors: 10%

Aimedis is mobile and comes with lots of cool features

  • Fully responsive: In every real browser
  • Multiple languages: Also fully functional overseas
  • Easy to use: Also for inexperienced patients simple & fast

image.png

THE AIMEDIS ROADMAP UNTIL 2022

  • Q1 2020: Aimedis V2 Launched
  • Q2 2020: AIMChain 2.0 launched
  • Q3 2020: Aimedis platform registered as medical product CE certificate
  • Q4 2020: Aimedis V3 launched & apps updated
  • Q4 2020: Aimedis staff & HR launched
  • Q3 2020: Aimedis iOS & Android apps released
  • Q1 2021: New Aimedis blockchain protocol and AIMx
  • Q1 2021: Launch of Aimedis labs
  • Q2 2021: Launch of Aimedis Virtual Hospital
  • From 2022: Launch of Aimedis Social Media Network (AIMSocial)
    Q3/Q4 2021: Aimedis eShop & Pharmacy
  • Q3/Q4 2021: Launch of Aimedis DataXChange NFTs & data trading

 

This is what I can say in this article. If you need accurate and reliable information, you can visit their official link, which I have provided below:

Website: https://aimedis.io/aimx-nft-blockchain
WhitePaper: https://aimedis.io/static/media/AimedisWhitePaperUpdated.d752751a.pdf
Twitter: https://twitter.com/AimedisGlobal
Facebook: https://www.facebook.com/aimedisglobal
Linkedin: https://www.linkedin.com/company/aimedis/
Telegram: https://t.me/aimedisnews
Instagram: https://www.instagram.com/aimedisglobal/
Youtube: https://www.youtube.com/channel/UCRK4YOmEGst6kk54g13RK7A
Medium: https://aimedisglobal.medium.com/

 

Author:

Bitcointalk Username: Sharena Delon
BitcoinTalk Profile URL: https://bitcointalk.org/index.php?action=profile;u=2850996
Telegram Username: https://t.me/SharenaDelon
Wallet : 0x34bca8bb2d4dd87d53afb895799258bc2b069d78

Tidak ada komentar:

Posting Komentar

ReelStar

ReelStar ReelStar Introduction ReelStar is a revolutionary new mobile app that is set to change the way we create, share, and trade content....